• Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. 

  Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; Fenwick, K; Kozarewa, I; Gonzalez de Castro, D; Bhosle, J; O'Brien, M; Turner, NC; Popat, S; Downward, J (2015-01)

  Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ...
• A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. 

  Mateo, J; Olmos, D; Dumez, H; Poondru, S; Samberg, NL; Barr, S; Van Tornout, JM; Jie, F; Sandhu, S; Tan, DS; Moreno, V; LoRusso, PM; Kaye, SB; Schöffski, P (2016-04-12)

  BACKGROUND: The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by ...
• Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. 

  Frezza, AM; Jones, RL; Lo Vullo, S; Asano, N; Lucibello, F; Ben-Ami, E; Ratan, R; Teterycz, P; Boye, K; Brahmi, M; Palmerini, E; Fedenko, A; Vincenzi, B; Brunello, A; Desar, IME; Benjamin, RS; Blay, JY; Broto, JM; Casali, PG; Gelderblom, H; Grignani, G; Gronchi, A; Hall, KS; Mir, O; Rutkowski, P; Wagner, AJ; Anurova, O; Collini, P; Dei Tos, AP; Flucke, U; Hornick, JL; Lobmaier, I; Philippe, T; Picci, P; Ranchere, D; Renne, SL; Sbaraglia, M; Thway, K; Wagrodzki, M; Wang, W-L; Yoshida, A; Mariani, L; Kawai, A; Stacchiotti, S (2018-09-01)

  Importance: Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the ...
• Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. 

  Bisogno, G; Jenney, M; Bergeron, C; Gallego Melcón, S; Ferrari, A; Oberlin, O; Carli, M; Stevens, M; Kelsey, A; De Paoli, A; Gaze, MN; Martelli, H; Devalck, C; Merks, JH; Ben-Arush, M; Glosli, H; Chisholm, J; Orbach, D; Minard-Colin, V; De Salvo, GL; European paediatric Soft tissue sarcoma Study Group (2018-08)

  BACKGROUND: Rhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug ...
• Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). 

  Shi, Q; Schmitz, N; Ou, F-S; Dixon, JG; Cunningham, D; Pfreundschuh, M; Seymour, JF; Jaeger, U; Habermann, TM; Haioun, C; Tilly, H; Ghesquieres, H; Merli, F; Ziepert, M; Herbrecht, R; Flament, J; Fu, T; Coiffier, B; Flowers, CR (2018-09-01)

  Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed ...
• Detection of circulating tumour cell clusters in human glioblastoma. 

  Krol, I; Castro-Giner, F; Maurer, M; Gkountela, S; Szczerba, BM; Scherrer, R; Coleman, N; Carreira, S; Bachmann, F; Anderson, S; Engelhardt, M; Lane, H; Evans, TRJ; Plummer, R; Kristeleit, R; Lopez, J; Aceto, N (2018-08)

  Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular ...
• RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. 

  Rodrigues, DN; Casiraghi, N; Romanel, A; Crespo, M; Miranda, S; Rescigno, P; Figueiredo, I; Riisnaes, R; Carreira, S; Sumanasuriya, S; Gasperini, P; Sharp, A; Mateo, J; Makay, A; McNair, C; Schiewer, M; Knudsen, K; Boysen, G; Demichelis, F; de Bono, JS (2018-09-26)

  Purpose: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal but clinically heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic treatments. Intrapatient genomic ...
• Association between information provision and supportive care needs among ovarian cancer survivors: A cross-sectional study from the PROFILES registry. 

  Rietveld, MJA; Husson, O; Vos, MCC; van de Poll-Franse, LV; Ottevanger, PBN; Ezendam, NPM (2018-08)

  OBJECTIVE: To examine the association between satisfaction with perceived information provision during diagnosis and treatment and supportive care needs in ovarian cancer survivors. METHODS: In 2012, women (n = 348) diagnosed ...
• Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. 

  Jones, RL; Le Cesne, A; Ibrahim, T; Garcia Del Muro, X; Menge, F (2018-12)

  INTRODUCTION: Health-related quality of life (HRQoL) is a patient-reported outcome that addresses patients' perceptions of symptoms across physical, emotional, cognitive and social domains. As HRQoL is currently rarely ...
• Health economic impact of liquid biopsies in cancer management. 

  IJzerman, MJ; Berghuis, AMS; de Bono, JS; Terstappen, LWMM (2018-12)

  INTRODUCTION: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a ...
• Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. 

  Athauda, A; Watkins, D; Mohammed, K; Chau, I; Starling, N; Rao, S; Tait, D; Aitken, K; Cunningham, D (2018-10)

  BACKGROUND/AIM: Cisplatin-based radical chemoradiotherapy (CRT) is utilised in oesophagogastric (OG) cancer but the toxicity profile of cisplatin limits its use. This study aimed to evaluate the clinical characteristics ...
• Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. 

  Owen, C; Constantinidou, A; Miah, AB; Thway, K; Fisher, C; Benson, C; Zaidi, S; Messiou, C; VAN DER Graaf, WTA; Jones, RL (2018-09)

  BACKGROUND/AIM: Synovial sarcoma is a soft tissue sarcoma that tends to affect young adults. There are few reports on primary synovial sarcoma of the thyroid and the aim of this study was to document the clinical and ...
• Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial. 

  Bhattacharya, IS; Haviland, JS; Kirby, AM; Kirwan, CC; Hopwood, P; Yarnold, JR; Bliss, JM; Coles, CE; IMPORT Trialists (2018-12-11)

  PURPOSE: IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported ...
• Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004). 

  Nutting, CM; Morden, JP; Beasley, M; Bhide, S; Cook, A; De Winton, E; Emson, M; Evans, M; Fresco, L; Gollins, S; Gujral, D; Harrington, K; Joseph, M; Lemon, C; Luxon, L; van den Blink, Q; Mendes, R; Miah, A; Newbold, K; Prestwich, R; Robinson, M; Sanghera, P; Simpson, J; Sivaramalingam, M; Srihari, NN; Sydenham, M; Wells, E; Witts, S; Hall, E; COSTAR Investigators (2018-11)

  PURPOSE: About 40-60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the ...
• BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 

  Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; Protheroe, A; Bogle, R; Blazeby, J; Palmer, A; Cresswell, J; Johnson, M; Brough, R; Madaan, S; Andrews, S; Cruickshank, C; Burnett, S; Maynard, L; Hall, E; BOXIT Investigators (2018-09-29)

  BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE: To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk ...
• What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK 

  Duley, L; Gillman, A; Duggan, M; Belson, S; Knox, J; McDonald, A; Rawcliffe, C; Simon, J; Sprosen, T; Watson, J; Wood, W (2018-12)
• A four-gene decision tree signature classification of triple-negative breast cancer: Implications for targeted therapeutics. 

  Quist, J; Mirza, H; Cheang, MCU; Telli, ML; O'Shaughnessy, J; Lord, CJ; Tutt, ANJ; Grigoriadis, A (2018-10-10)

  The molecular complexity of triple-negative breast cancers (TNBCs) provides a challenge for patient management. We set out to characterise this heterogeneous disease by combining transcriptomics and genomics data, with the ...
• Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. 

  Robinson, M; James, J; Thomas, G; West, N; Jones, L; Lee, J; Oien, K; Freeman, A; Craig, C; Sloan, P; Elliot, P; Cheang, M; Rodriguez-Justo, M; Verrill, C; UK National Cancer Research Institute (NCRI) Cellular-Molecular Pathology (CM-Path) clinical trials working group (2018-11-08)

  While pathologists have always played a pivotal role in clinical trials ensuring accurate diagnosis and staging, pathology data from prognostic and predictive tests are increasingly being used to enrol, stratify and randomise ...
• Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. 

  Chew, W; Benson, C; Thway, K; Hayes, A; Miah, A; Zaidi, S; Lee, ATJ; Messiou, C; Fisher, C; van der Graaf, WT; Jones, RL (2018-09-05)

  BACKGROUND: Sclerosing epithelioid fibrosarcoma (SEF) is a very rare soft tissue sarcoma subtype. Clinically it is an aggressive tumour; however, to our knowledge there are no published reports regarding the efficacy of ...
• Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. 

  Pender, A; Davis, EJ; Chauhan, D; Messiou, C; Al-Muderis, O; Thway, K; Fisher, C; Zaidi, S; Miah, A; Judson, I; van der Graaf, W; Keedy, VL; Benson, C; Jones, RL (2018-08-20)

  The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following ...

View more